

May 29, 2020

Name of listed company: Chugai Pharmaceutical Co., Ltd.  
Code number: 4519 (1<sup>st</sup> Section of Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo  
Chairman & CEO: Tatsuro Kosaka  
Inquiries to: Masahiko Uchida,  
Head of Corporate Communications Dept.  
Tel: +81-(0)3-3273-0881

## **Chugai Files Patent Infringement Lawsuit concerning Ediol Capsules against Sawai and Nichi-Iko**

[Chugai Pharmaceutical Co., Ltd.](#) announced today that it has filed a patent infringement lawsuit with the Tokyo District Court and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the generic drugs of an osteoporosis agent, active vitamin D<sub>3</sub> derivative Ediol® Capsule 0.5µg / 0.75µg (generic name: eldecacitol, hereafter, Ediol Capsule), against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd., the marketing authorization holders of generic versions of the drug, citing such parties' infringement of a use patent owned by Chugai and Taisho Pharmaceutical Co., Ltd.

1. Date of Complaint

May 29, 2020

2. Reasons for the Action

On February 17, 2020, Sawai and Nichi-Iko received approval from the Ministry of Health, Labour and Welfare for their generic drugs of Ediol Capsule, respectively. Chugai and Taisho currently co-market Ediol Capsule wherein Chugai alleged that the generic drugs of Ediol Capsule infringe both companies' use patent (patent number 5969161) , and filed an injunction with the Tokyo District Court against the manufacture, transfer, import, and offer of any transfer regarding the generic drugs, and disposal of stock.

3. Defendants

- (1) Name: Sawai Pharmaceutical Co., Ltd.  
Address: 5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan  
(2) Name: Nichi-Iko Pharmaceutical Co., Ltd.  
Address: 1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan

4. Prospects

No changes are expected to Chugai's financial prospects at this point.

###